

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 November 2003 (20.11.2003)

PCT

(10) International Publication Number  
**WO 03/094919 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 31/496,**  
C07D 401/04

(21) International Application Number: PCT/US03/14811

(22) International Filing Date: 12 May 2003 (12.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/379,510	10 May 2002 (10.05.2002)	US
60/389,093	14 June 2002 (14.06.2002)	US
60/401,672	6 August 2002 (06.08.2002)	US
60/402,749	12 August 2002 (12.08.2002)	US
60/409,860	10 September 2002 (10.09.2002)	US
60/423,338	1 November 2002 (01.11.2002)	US
60/432,961	12 December 2002 (12.12.2002)	US
60/444,812	3 February 2003 (03.02.2003)	US
60/448,062	15 February 2003 (15.02.2003)	US

(71) Applicant (for all designated States except BB, US): **TEVA PHARMACEUTICAL INDUSTRIES LTD.** [IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petah Tiqva (IL).

(71) Applicant (for BB only): **TEVA PHARMACEUTICALS USA, INC.** [US/US]; 1090 Horsham Road, P.O. Box 1090, North Wales, PA 19454-1090 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NIDDAM-HILDESHEIM, Valerie** [IL/IL]; 9 Keren Hayessod,

PO 1343, 40500 Even-Yeouda (IL). **WIZEL, Shlomit** [IL/IL]; Yehuda Hanassi 2, 49742 Petah Tiqva (IL). **STER-IMBAUM, Greta** [IL/IL]; 10/10 Kaplinsky St., Rishon, 75241 Lezion (IL). **AMIR, Ehud** [IL/IL]; 73 Einstein Street, Apartment 20, Ramat Aviv, 69102 Tel Aviv (IL).

(74) Agents: **BRAINARD, Charles, R.**; Kenyon & Kenyon, One Broadway, New York, NY 10004-1050 et al. (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/094919 A2

(54) Title: NOVEL CRYSTALLINE FORMS OF GATIFLOXACIN

(57) Abstract: Provided are novel crystalline forms of gatifloxacin denominated forms A, B, C, D, E1, F, G, H, I, and J, and methods for their preparation. Also provided are methods for making known crystalline forms of hatifloxacin, in particular forms omega and T2RP.

**NOVEL CRYSTALLINE FORMS OF GATIFLOXACIN****FIELD OF THE INVENTION**


The present invent relates to novel polymorphs and pseudopolymorphs of ( $\pm$ ) 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, commonly known as gatifloxacin.

**RELATED APPLICATIONS**

The present application claims the benefit of the filing date of the following United States Provisional Patent Applications: 60/379,510; 60/389,093; 60/401,672; 60/402,749; 60/409,860, 60/423,338; 60/432,961; 60/444,812; and 60/448,062.

**BACKGROUND OF THE INVENTION**

Gatifloxacin, known as ( $\pm$ ) 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, has the following structure:



Gatifloxacin, an anti-bacterial agent, is marketed as Tequin<sup>®</sup> by Bristol-Myers Squibb. Tequin<sup>®</sup> is available in a dosage of 200 and 400mg in the form of a vial or a tablet, which can be either injected or taken orally.

Many pharmaceutically active organic compounds can crystallize in more than one type of molecular packing with more than one type of internal crystal lattice. That is, the compounds crystallize in different crystalline forms. The respective resulting crystal structures (forms) can have, for example, different unit cells. This phenomenon – identical chemical structure but different internal structure – is referred to as polymorphism and the species having different molecular structures are referred to as polymorphs.

Many pharmacologically active organic compounds can also crystallize in crystalline forms such that second, foreign molecules, especially solvent molecules, are regularly incorporated into the crystal structure of the principal pharmacologically active compound. This phenomenon is sometimes referred to as pseudopolymorphism and the resulting structures as pseudopolymorphs. When the second molecule is a solvent molecule, the pseudopolymorphs can be referred to as solvates.

However, it is generally not possible to predict whether a particular organic compound will form different crystalline forms, let alone predict the structure and properties of the crystalline forms themselves.

The discovery of a new crystalline form of a pharmaceutically useful compound provides an opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for designing, for example, a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristic. It is clearly advantageous when this repertoire is enlarged by the discovery of new polymorphs or pseudopolymorphs of a useful compound. For a general review of polymorphs and the pharmaceutical applications of polymorphs see G.M. Wall, *Pharm Manuf.* 3, 33 (1986); J.K. Haleblian and W. McCrone, *J. Pharm. Sci.*, 58, 911 (1969); and J.K. Haleblian, *J. Pharm. Sci.*, 64, 1269 (1975), all of which are incorporated herein by reference.

Crystalline forms can be influenced by controlling the conditions under which the compound is obtained in solid form. Solid state physical properties that can differ from one polymorph to the next include, for example, the flowability of the milled solid. Various crystalline forms can be more or less hygroscopic. Absorption of atmospheric moisture by compound in powder form can impede its ability to flow. Flowability affects the ease with which the material is handled during processing into a pharmaceutical product. When particles of the powdered compound do not flow past each other easily, a formulation specialist must take that fact into account in developing a tablet or capsule formulation, which may necessitate the use of glidants such as colloidal silicon dioxide, talc, starch or tribasic calcium phosphate.

Another important solid state property of a pharmaceutical compound that can vary from one polymorph or pseudopolymorph to the next is its rate of dissolution in aqueous media, e.g., gastric fluid. The rate of dissolution of an active ingredient in a

patient's stomach fluid can have therapeutic consequences since it imposes an upper limit on the rate at which an orally-administered active ingredient can reach the patient's bloodstream. The rate of dissolution is also a consideration in formulating syrups, elixirs and other liquid medicaments. The solid state form of a compound may also affect its behavior on compaction and its storage stability.

These practical physical characteristics are influenced by the conformation, orientation, and packing of molecules in the unit cell, which characterize a particular polymorphic or pseudopolymorphic form of a substance. A polymorphic form may have thermodynamic properties different from those of the amorphous material or another polymorphic form. Thermodynamic properties can be used to distinguish between various polymorphs or pseudopolymorphs. Thermodynamic properties that can be used to distinguish between polymorphs and pseudopolymorphs can be measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and differential thermal analysis (DTA).

A particular crystalline form can also possess distinct spectroscopic properties that may be detectable by, for example, solid state  $^{13}\text{C}$  NMR spectroscopy and infrared (IR) spectroscopy. This is particularly so in the case of crystalline forms that are solvates because of the presence of absorptions or resonances due to the second, foreign molecule.

(±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolenecarboxylic acid, commonly known as gatifloxacin, is a synthetic broad-spectrum antibacterial agent for oral or intravenous administration.

United States Patent 5,880,283 discloses that gatifloxacin forms a hygroscopic hemihydrate. The hemihydrate (a pseudopolymorph) is reported to be easily formed upon crystallization of gatifloxacin from water-containing organic solvents. The hemihydrate reportedly has disadvantages for manufacturing of solid oral dosage forms, e.g., tablets. The patent further discloses a novel pseudopolymorph of gatifloxacin, the sesquihydrate, and presents thermal analysis and x-ray diffraction data for this material. The sesquihydrate is reported to be less hygroscopic and more stable in manufacturing.

U.S. Pat. No. 6,413,969 discloses at least 12 different polymorphs or pseudopolymorphs of gatifloxacin and discloses the x-ray powder diffraction diagrams of at least 10 of these. The hexahydrate, pentahydrate and sesquihydrate are crystallized directly from aqueous solvents. Other crystalline forms are crystallized from a molten

phase or by solid-solid phase transformations. The pentahydrate form is, according to the disclosure of U.S. Pat. No. 6,413,969, the most thermodynamically stable form and has the lowest aqueous solubility at room temperature. The interrelationships between the twelve identified crystalline forms are given in the application.

5

### SUMMARY OF THE INVENTION

In one aspect, the present invention the present invention relates to crystalline form of gatifloxacin, denominated form A, characterized by x-ray reflections at about  $6.4^\circ$ ,  $12.8^\circ$ ,  $16.4^\circ$ ,  $17.3^\circ$ , and  $19.4^\circ \pm 0.2^\circ 2\theta$ .

10 In another aspect the present invention relates to a crystalline form of gatifloxacin, denominated form B, characterized by x-ray reflections at about  $9.2^\circ$ ,  $10.6^\circ$ ,  $11.9^\circ$ ,  $18.4^\circ$ , and  $25.0^\circ \pm 0.2^\circ 2\theta$ ; and to a method for making it, which method includes the steps of slurrying gatifloxacin in a lower alkanol selected from ethanol and 1-butanol at ambient temperature for a slurry time, especially about 8 to about 36 hours, and isolating crystalline form B of gatifloxacin from the slurry.

15 In another aspect, the present invention relates to crystalline form of gatifloxacin, denominated form C, having at least one characteristic selected from:

- a) x-ray reflections at about  $7.2^\circ$ ,  $10.8^\circ$ ,  $15.8^\circ$ ,  $21.8^\circ$ , and  $26.2^\circ \pm 0.2^\circ 2\theta$ ,
- b) DSC endotherms at about  $173^\circ$  and  $177^\circ$  C, and
- c) FTIR absorption bands at about 805, 1509, 1619, and  $1728\text{ cm}^{-1}$ .

20 In a related aspect, the present invention relates to a method of making gatifloxacin form C including the step of heating either of gatifloxacin form B or form I at about  $40^\circ$  to about  $70^\circ$  C, especially  $50^\circ$  C, and atmospheric pressure for about 25 to about 48 hours.

25 In yet another aspect, the present invention relates to a crystalline form of gatifloxacin, denominated form D, characterized by x-ray reflections at about  $8.2^\circ$ ,  $14.4^\circ$ ,  $19.0^\circ$ ,  $21.4^\circ$ ,  $21.9^\circ$ , and  $23.1^\circ \pm 0.2^\circ 2\theta$ , and to a method of making it, which method includes the steps of slurrying gatifloxacin in methanol at ambient temperature for a slurry time, especially about 8 to about 36 hours, and isolating the crystalline form of gatifloxacin from the slurry.

30 In another aspect, the present invention relates to a method of making form D including the step of incubating gatifloxacin in vapors of methanol.

In a further aspect, the present invention relates to a crystalline form of gatifloxacin, denominated form F, characterized by x-ray reflections at  $8.0^\circ$ ,  $14.2^\circ$ ,  $18.7^\circ$ ,  $21.8^\circ$ , and  $23.0^\circ \pm 0.2^\circ 2\theta$ ; and to a method of making it, which method includes the steps of

- 5                   a) providing a solution of gatifloxacin in a mixture of methanol and water, 90:10 (v:v),
- b) cooling the solution, especially to ambient temperature or below, especially about  $5^\circ\text{C}$ , and
- c) isolating the crystalline form of gatifloxacin.

10           In another aspect, the present invention relates to crystalline form of gatifloxacin, denominated form G, characterized by at least one of:

- a) x-ray reflections at about  $17.2^\circ$  and  $17.6^\circ \pm 0.2^\circ 2\theta$ , and
- b) FTIR absorption bands at about  $1614\text{ cm}^{-1}$  and about  $1267\text{ cm}^{-1}$ .

15           In a further aspect, the present invention relates to a method of making gatifloxacin crystalline form G including the step of drying either of gatifloxacin crystalline forms A or F at  $50^\circ\text{C}$  and atmospheric pressure for at least about 20 hours.

20           In yet another aspect, the present invention relates to a crystalline form of gatifloxacin, denominated form H, characterized by x-ray reflections at about  $6.6^\circ$ ,  $13.2^\circ$ ,  $19.6^\circ$ , and  $19.9^\circ \pm 0.2^\circ 2\theta$ ; and to a method of making it, which method includes the steps of:

- a) providing a solution of gatifloxacin in toluene, especially at reflux
- b) cooling the solution, especially to ambient temperature or below, especially about  $-5^\circ\text{C}$ , and
- c) isolating the crystalline form of gatifloxacin.

25           In another aspect, the present invention relates to gatifloxacin toluene solvate.

                  In another aspect, the present invention relates to a method of making gatifloxacin crystalline form H including the steps of:

- a) slurrying gatifloxacin in toluene at ambient temperature for a slurry time, especially about 8 to about 36 hours, and
- 30               b) isolating the crystalline form of gatifloxacin from the slurry.



In a further aspect, the present invention relates to a crystalline form of gatifloxacin, denominated form I, characterized by x-ray reflections at 6.5°, 7.1°, 12.8°, 17.2°, 19.3°, and  $21.0^\circ \pm 0.2^\circ$ , and to a method of making it, which method includes the steps of:

- 5                   a) providing a solution of gatifloxacin in 1-butanol, especially at reflux  
                  b) cooling the solution, especially to ambient temperature or below, especially about -5°, and  
                  c) isolating the crystalline form of gatifloxacin from the suspension.

10           In still yet another aspect, the present invention relates to a crystalline form of gatifloxacin that exists in various solvated forms, denominated form J, characterized by a x-ray reflection at about 6.7°, 11.3°, 13.8°, and  $16.4^\circ \pm 0.2^\circ 2\theta$ . Form J can exist at least as an iso-propanol solvate, that can be made by an incubation process or a crystallization process; a methyl ethyl ketone solvate that can be made by an incubation process; an acetone solvate that can be made by an incubation process or slurry process; a 1-butanol  
15           solvate that can be made by a crystallization process; or as a tetrahydrofuran solvate that can be made by a slurry process.

          In still yet another aspect, the present invention relates to a crystalline form of gatifloxacin, denominated form E1, characterized by x-ray reflections at about 7.1°, 7.3°, 10.8°, 15.7°, 16.4°, and  $18.1^\circ \pm 0.2^\circ 2\theta$ ; and to methods for making it. Form E1 contains  
20           acetonitrile, water, or a mixture of acetonitrile and water at up to about 10 wt%.

          In another aspect, the present invention relates to a crystalline form of gatifloxacin, E1-ACN, and to methods of making it. E1-ACN has the crystallographic characteristics of E1, namely x-ray reflections at about 7.1°, 7.3°, 10.8°, 15.7°, 16.4°, and  $18.1^\circ \pm 0.2^\circ 2\theta$ ; and contains up to about 10% acetonitrile.

25           Gatifloxacin E1-ACN can be made by a process including the steps of:

- a) providing a solution of gatifloxacin in acetonitrile having about 5 wt% or less water, especially about 4.5 wt% or less water, at reflux,  
                  b) cooling the solution to a seeding temperature of about 57° to 70°C, especially about 60° C,  
30               c) seeding the solution at the seeding temperature and, optionally, maintaining the seeded solution at the seeding temperature for a seeding time of about 30 minutes or more,

d) cooling the seeded solution, especially to ambient temperature or below, especially 5°C or below, and

e) isolating the crystalline E1-ACN gatifloxacin.

In still a further aspect, the present invention relates to a hydrate form E1 having a water content of about 7.5 to about 10 weight percent (wt%). In a particular aspect, the present invention relates to a hydrated form of gatifloxacin that is a dihydrate (E1 dihydrate) having about 9.3 weight percent water. The hydrated E1 of the present invention, regardless of water content, is substantially free of prior-art sesquihydrate and is characterized by x-ray reflections at about 7.1°, 7.3°, 10.8°, 15.7°, 16.4°, and 18.1° ± 0.2° 2θ.

In a further aspect, the present invention relates to methods of making hydrated E1, which method includes the step of treating gatifloxacin form E1-ACN solvate with a moist gas, especially moist gas of about 55% to about 75% relative humidity at a temperature from ambient temperature to about 60° C, especially about 20° to 30° C; although treating at 50° C can be advantageous.

In still a further aspect, the present invention relates to a method of making prior-art crystalline form of gatifloxacin, denominated form omega (Ω), including the steps of:

a) providing, at reflux, a filtered solution of gatifloxacin in acetonitrile, wherein the solution has a water content of about 5% or less, especially about 4.5 wt% or less,

b) cooling the solution to a seeding temperature of about 50° to about 56° C

c) seeding the solution with gatifloxacin at the seeding temperature and, optionally, maintaining the seeded solution at the seeding temperature for a seeding time of at least about 30 minutes,

d) cooling the seeded solution, especially to ambient temperature or below, especially about 5°C, and

e) isolating the crystalline gatifloxacin crystalline form omega from the suspension.

In still a further aspect, the present invention relates to method of making prior-art crystalline form of gatifloxacin T2RP. In one such method, > 200g (especially > 1000 g) of gatifloxacin E1-ACN are slurried with ethanol and the solid isolated from the slurry is

treated with moist gas, especially in a fluidized bed apparatus. Other methods including the step of treating novel forms of gatifloxacin are also disclosed.

In another aspect, the present invention relates to a method of making about 200g or less of gatifloxacin form T2RP including the steps of slurrying about 200 g or less of  
5 gatifloxacin E1-ACN in ethanol, isolating the solid from the slurry, and drying the isolated solid at about 50° C.

In another aspect, the present invention relates to gatifloxacin having an average particle size less than about 100 $\mu$ , especially less than about 50 $\mu$ , wherein the gatifloxacin is in a crystalline form selected from forms A, B, C, D, hydrated E1, F, G, H, I, and J.

10 In yet still another aspect, the present invention relates to pharmaceutical compositions containing a hydrated form of gatifloxacin form E1, especially E1 dihydrate, that are substantially free of sesquihydrate.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 shows a representative x-ray diffraction diagram of gatifloxacin form A.  
15 Figure 2 shows a representative DSC thermogram of gatifloxacin form A.  
Figure 3 shows a representative TGA thermogram of gatifloxacin form A.  
Figure 4 shows a representative x-ray diffraction diagram of gatifloxacin form B.  
Figure 5 shows a representative DSC thermogram of gatifloxacin form B.  
Figure 6 shows a representative TGA thermogram of gatifloxacin form B.  
20 Figure 7 shows a representative x-ray diffraction diagram of gatifloxacin form C.  
Figure 8 shows a representative FTIR spectra for gatifloxacin form C.  
Figure 9 shows a representative DSC thermogram of gatifloxacin form C.  
Figure 10 shows a representative TGA thermogram of gatifloxacin form C.  
Figure 11 shows a representative x-ray diffraction diagram of gatifloxacin form D.  
25 Figure 12 shows a representative DSC thermogram of form D.  
Figure 13 shows a representative TGA thermogram of form D.  
Figure 14a through 14g show representative x-ray diffraction diagrams of gatifloxacin form E1.

Figure 15 shows a representative TGA thermogram of gatifloxacin form E1 dihydrate.

Figure 16 shows a representative TGA thermogram of gatifloxacin form E1 as its acetonitrile solvate.

5 Figure 17 shows a representative x-ray diffraction diagram of gatifloxacin form F.

Figure 18 shows a representative DSC thermogram of form F.

Figure 19 shows a representative TGA thermogram of form F.

Figure 20 shows a representative x-ray diffraction diagram of gatifloxacin form G.

Figure 21 shows a representative FTIR spectrum of gatifloxacin form G.

10 Figure 22 shows a representative DSC thermogram of gatifloxacin form G.

Figure 23 shows a representative TGA thermogram of gatifloxacin form G.

Figure 24 shows a representative x-ray diffraction diagram of gatifloxacin form H toluene solvate.

15 Figure 25 shows a representative DSC thermogram of gatifloxacin form H toluene solvate.

Figure 26 shows a representative TGA thermogram of gatifloxacin form H toluene solvate.

Figure 27 shows a representative x-ray diffraction diagram of gatifloxacin form I.

Figure 28 shows a representative DSC thermogram of gatifloxacin form I.

20 Figure 29 shows a representative TGA thermogram of gatifloxacin form I.

Figure 30 shows a representative FTIR spectrum of gatifloxacin form J.

Figure 31 shows a representative DSC thermogram of gatifloxacin form J.

Figure 32 shows a representative TGA thermogram of gatifloxacin form J.

### **DETAILED DESCRIPTION OF THE INVENTION**

25 Gatifloxacin, ( $\pm$ ) 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, is a known anti-bacterial. The present invention provides novel crystalline forms (polymorphs, pseudopolymorphs) of this useful drug.

Unless otherwise specified or required by the context, gatifloxacin refers to the compound in any crystalline form, which may or may not be a solvated crystalline form, or in an amorphous form.

As used herein, gatifloxacin form omega ( $\Omega$ ), form T1RP, and form T2RP refer to the crystalline forms disclosed under those designations in United States Patent 6,413,969. Gatifloxacin sesquihydrate refers to the crystalline form of gatifloxacin denominated as such in United States Patent 5,880,283.

As used herein, the phrase, "having at least one characteristic of GTF form '#'," where "#" is an arabic letter or numeral or a roman numeral, or any combination of these denoting a crystalline form of gatifloxacin, refers to a crystalline form of gatifloxacin that exhibits at least the characteristic powder x-ray diffraction (PXRD) reflections (or peaks), or the characteristic DSC endo- or exotherms, or, where applicable, the characteristic FTIR absorption bands of form '#'.

As used herein in connection with a measured quantity, the term, "about," refers to that variation in the measured quantity as would be expected by the skilled artisan making the measurement and exercising a level of care commensurate with the objective of the measurement and the precision of the measuring equipment used.

As used herein, the term ambient temperature is a temperature between about 18° and about 30° C.

As used herein, ambient pressure is about 760 mmHg.

As used herein in connection with drying procedures, drying under vacuum (*in vacuo*) implies drying at a reduced pressure of about 10 to about 20 mm Hg.

As used herein in connection with a multi-component mixture of liquids, the term % v/v refers to the ratio of the volume of the named component to the sum of the volumes of all components used to make the mixture, times 100. Thus, a mixture of approximately equal volumes of A and B is referred to as "50 vol-% A" (or 50 vol-% B). Alternatively, this mixture can be referred to as "a mixture of A and B, 50:50 (v:v)".

As used herein, lower alkanol refers to an alcohol of formula  $C_nH_{2n+1}OH$ , where n is 6 or less.

X-ray reflections reported herein were determined by the powder diffraction technique (PXRD). X-ray powder diffraction analysis was performed using a Scintag powder diffractometer with variable goniometer, a Cu source, and a solid state detector. A standard round aluminum sample holder with zero background quartz plate was used.

Samples were scanned from 2° to 40° 2θ at 3° per minute. Reflections are reported as peak maxima in the Intensity vs. 2θ plots, and are subject to the normal experimental error (uncertainty) of ± 0.2°. Wet samples were promptly analyzed “as is,” i.e., without drying or grinding prior to the analysis.

5            Fourier transform infra-red spectra (FTIR) were obtained on Nujoll mulls using a Perkin Elmer SpectrumOne spectrophotometer. Sixteen scans were recorded from 4000 to 400 cm<sup>-1</sup> at a resolution of 4 cm<sup>-1</sup>.

Differential scanning calorimetric (DSC) analysis was performed with a Mettler Toledo DSC 821<sup>e</sup> calorimeter. Samples of about 3 to about 5 milligrams, held in a vented  
10 (3-hole) crucible, were analyzed at a heating rate of 10° per minute.

Thermogravimetric analysis (TGA) was performed using a Mettler TG50 thermobalance. Samples of 7 to 15 milligrams were analyzed at a heating rate of 10° C per minute in the temperature range between about 25° C and about 200° C.

The water content (wt-% water) of crystalline forms of gatifloxacin reported  
15 herein was determined by the Karl-Fisher method. Water content of solutions was likewise determined by the Karl-Fisher method.

In particular embodiments, a novel crystalline form of the present invention is made by a crystallization (precipitation) process in which a particular crystalline form of gatifloxacin is crystallized from a solution in an organic solvent. The solvent can be a  
20 single component (i.e., a single organic compound normally liquid at ambient temperature), or it can be multi-component (i.e., a mixture of organic compounds normally liquid at ambient temperature). One of the components of a multi-component solvent can be a poor solvent for gatifloxacin. Crystallization can be induced by changing the solubility of gatifloxacin in the solvent. The solubility can be altered by, for  
25 example, lowering the temperature of the solution, or by adding an “anti-solvent” to the solution.

In particular embodiments, filtration of the solution from which the crystalline form of gatifloxacin is to be crystallized has been found to be an important step. Although an understanding of the theory of the importance of this filtration step is  
30 unnecessary to the practice of the present invention, the present inventors speculate that filtration, especially hot filtration, removes and promotes control of the temperature at which nucleation can be sustained and crystallization begins. Both of these are parameters capable of influencing the crystalline form of gatifloxacin obtained.

The temperature of the solution can be lowered in one or more steps. For making certain crystalline forms, it is advantageous to lower the temperature in steps and to maintain the temperature at each step for a holding time (i.e., a first holding time at the temperature at the end of the first cooling step, a second holding time at the temperature at the end of the second cooling step, etc.). Step-wise lowering of the temperature can be advantageous when seeding is employed. Seeding is a well-known technique for inducing crystallization of a compound from its solution. When seeding is employed, the solution is cooled into a seeding temperature in a first cooling step. The temperature at which the solution is seeded is denoted the seeding temperature and the holding time at that temperature is known as a seeding time. It is sometimes necessary to carefully control the cooling rate of any cooling step, depending on the crystalline form of gatifloxacin being sought.

The skilled artisan will appreciate that in any method of the present invention in which a solution of gatifloxacin is provided, the solution can be provided by any means; for example by dissolving gatifloxacin in the solvent or, where the solvent does not interfere with the reaction, by preparing gatifloxacin in the presence of the desired solvent, or in the presence of one component of a multi-component solvent system whereafter other component(s) are introduced.

An anti-solvent is an organic compound, normally a liquid at ambient temperature, that is a poor solvent for the compound to be crystallized (here gatifloxacin). The solubility of the compound to be crystallized from the combination of solvent and anti-solvent is lower than the solubility of the compound in the original solvent. In particular embodiments, crystallization is induced through use of an anti-solvent and by lowering the temperature of the solution.

The crystalline form of gatifloxacin is then isolated by standard means.

In other embodiments, a novel crystalline form of gatifloxacin of the present invention is made in a slurry (suspension) process in which gatifloxacin is slurried (suspended), with agitation, in a slurry solvent, usually at ambient temperature, for a slurry time. As long as there is sufficient slurry solvent to wet and suspend the gatifloxacin, the ratio of gatifloxacin to slurry solvent is not critical and will be dictated by practical considerations, for example, ease of handling. The slurry time is not critical and will usually be between about 8 and about 36 hours. The skilled artisan will know to

adjust the slurry time by routine optimization by, for example, isolating the solid from a small aliquot of the slurry and determining the crystalline form of the solid by an appropriate technique, for example x-ray diffraction, differential scanning calorimetry, or Fourier transform infra-red spectroscopy.

5           At the end of the slurry time, the crystalline form of gatifloxacin is isolated by standard techniques, for example filtration (gravity or suction) or centrifugation, to mention just two.

          In other embodiments, a novel crystalline form of gatifloxacin of the present invention is made by treating a vapor incubation process wherein gatifloxacin is exposed  
10 to (i.e., incubated with) vapors of an organic solvent, usually at ambient temperature, for an incubation time. Any suitable chamber capable of holding the sample and containing the solvent vapors can be used. The incubation time is not critical and will generally be between about 2 and about 20 days.

          In those embodiments that yield a crystalline form of gatifloxacin that is a solvate,  
15 care should be taken to analyze the material without drying that might remove the solvent.

          One or more of the foregoing methods, and other methods such as thermal treatment (heating, drying) described hereinbelow, are adapted to the preparation of the novel crystalline forms of gatifloxacin of the present invention.

20           In one embodiment, the present invention provide a crystalline form of gatifloxacin, denominated form A, which is characterized by x-ray reflections at about 6.4°, 12.8°, 16.4°, 17.3°, and  $19.4^\circ \pm 0.2^\circ 2\theta$ . A typical x-ray diffraction diagram of form A is shown in Figure 1. A typical DSC thermogram of form A is shown in Figure 2. The loss on drying of form A, as determined by TGA, can be as high as 65%. A typical TGA  
25 thermogram of form A is shown in Figure 3.

          Form A can be made by a slurry process including the steps of slurrying gatifloxacin in iso-propanol (IPA) at ambient temperature and isolating the crystalline form A.

          Form A can be converted to form J by, for example, drying at 50°C. The skilled  
30 artisan will know to adjust the drying time according to, for example, sample size and



drying equipment used. Generally, a time of about 12 to about 18 hours is sufficient to effect the conversion.

In another embodiment, the present invention provides a novel crystalline form of gatifloxacin, denominated form B, characterized by x-ray diffraction reflections at  $2\theta =$   
5 9.2°, 10.6°, 11.9°, 18.4°, and 25.0°. A typical x-ray diffraction diagram for form B is shown in Figure 4. A typical DSC thermogram of form B is shown in Figure 5. A typical TGA thermogram of form B is shown in Figure 6.

Gatifloxacin crystalline form B can be made in a slurry process including the steps of slurrying gatifloxacin at ambient temperature in either 1-butanol or ethanol and  
10 recovering the gatifloxacin form B.

In still another embodiment, the present invention provides a novel crystalline form of gatifloxacin, denominated form C, that can be characterized by one or more of  
a) x-ray reflections at about 7.2°, 10.8°, 15.8°, 21.8°, and  $26.2^\circ \pm 0.2^\circ 2\theta$ ,  
b) DSC endotherms at about 173° and 177° C, and  
15 c) FTIR absorption bands at about 805, 1509, 1619, and 1728  $\text{cm}^{-1}$ .

A typical x-ray diffraction diagram of form C is shown in Figure 7. A typical FTIR spectrum for form C is shown in Figure 8. A typical DSC thermogram of form C is shown in Figure 9. A typical TGA thermogram of form C is shown in Figure 10.

Form C can be made by, for example, drying form B, described above, at ambient  
20 pressure and about 60°C, or at about 50°C and 10 to 20 mm Hg. Form C can also be made by drying form I, described hereinbelow, at about 50° to about 60°C.

In another embodiment, the present invention provides a novel crystalline form of gatifloxacin, denominated form D, characterized by x-ray reflections at about 8.2°, 14.4°, 19.0°, 21.4°, 21.9°, and  $23.1^\circ \pm 0.2^\circ 2\theta$ . A typical x-ray diffraction diagram for form D is  
25 shown in Figure 11. A typical DSC thermogram of form D is shown in Figure 12. Form D has a loss on drying of about 13 wt%. A typical TGA thermogram of form D is shown in Figure 13.

Form D can be made by either a slurry process or a vapor incubation process. The slurry process for making form D includes the steps of slurrying gatifloxacin with  
30 methanol and isolating gatifloxacin form D. In the vapor incubation process, gatifloxacin is incubated in vapors of methanol.

In still a further embodiment, the present invention provides a novel crystalline form of gatifloxacin, denominated form E1. Form E1 can be characterized by x-ray reflections at about 7.1°, 7.3°, 10.8°, 15.7°, 16.4°, and 18.1° ± 0.2° 2θ. Typical x-ray diffraction diagrams for different batches of form E1 are shown in Figures 14a through 14g, which suggest that small changes in the x-ray pattern may be observed in different batches, especially in the range of 19° to 30° 2θ.

Form E1 contains up to about 10% acetonitrile, water, or mixtures thereof. Form E1-ACN containing 8% to 10% acetonitrile can be referred to as monosolvate. The crystallographic properties of E1 are essentially insensitive to the presence of the solvent. The solvent can be driven-off by heating.

In a particular embodiment, the present invention provides a crystalline form of gatifloxacin, denominated E1-ACN, that has the crystallographic properties of E1 and contains up to about 10% acetonitrile. A typical TGA thermogram of E1-ACN is shown in Figure 16. Drying of E1-ACN at 70° to 170°C for at least about 30 minutes yields gatifloxacin form omega (Ω).

E1-ACN can be made by a crystallization process including the steps of providing, at reflux, a solution of gatifloxacin in acetonitrile, wherein the water content of the solution is about 5 wt% or less, preferably 4.5 wt% or less, cooling the solution to a seeding temperature between about 57° to 70°C, preferably about 60°C, seeding the solution with gatifloxacin, optionally maintaining the seeded solution at the seeding temperature for a seeding time of about 30 minutes or more, cooling the seeded solution to a temperature at which E1-ACN crystallizes, especially to ambient temperature or below, preferably about 5°C or below, and isolating the gatifloxacin E1-ACN. Typically, E1-ACN is isolated from a suspension.

The water content of the solution prior to seeding should be about 5 wt% or less, preferably 4.5 wt% or less, as determined by Karl-Fisher analysis. If necessary, the water content can be reduced by distilling-off acetonitrile-water azeotrope (replenishing acetonitrile as required).

E1-ACN can also be made by a vapor incubation method in which gatifloxacin is incubated with vapors of acetonitrile for about 5 to about 20 days.

In another embodiment, the present invention provides a hydrate form of  
gatifloxacin having the crystallographic properties of form E1. The hydrated form can  
but preferably does not also contain acetonitrile, with the proviso that the total amount of  
water and acetonitrile is about 10% or less. In a preferred embodiment, the hydrated form  
5 contains about 7.5% to about 10% water and is a dihydrate. A typical TGA thermogram  
of form E1 dihydrate is shown in Figure 15.

The crystallographic characteristics of hydrated form E1 are those of E1-ACN.  
Hydrated form E1 has a water content (Karl-Fisher) between about 5% and about 10%,  
preferably 7.5% to 10%. In a particular embodiment, the hydrated form of E1 is form E1  
10 dihydrate and contains about 9% water.

Hydrated form E1 can be made in a treating process including the step of treating  
E1-ACN with a moist gas, such as air, nitrogen, or a noble gas. Preferably, the moisture  
content of the gas is such that the gas has a relative humidity between about 55% and  
75%. The treating can be at any temperature from ambient up to about 60° C. Preferably,  
15 the treating is at about 20° to 30° C, most preferably 25°C.

Treating E1-ACN solvate with a moist gas at higher temperature than 30°C results  
in hydrated E1 that can contain 5% to 7% water. By treating the E1 product which  
contains 5% to 7% water with a moist gas (55% - 75% relative humidity) at 20° to 30°C,  
preferably 25°C, hydrated E1 (water content of 7.5% to 10%) is obtained. In preferred  
20 embodiments, E1 dihydrate of 9.3% water content is obtained.

Any apparatus that allows for circulation or percolation of moist gas around and  
between particles of the E1-ACN can be used. Fluidized bed apparatus, well known in  
the art, is particularly well suited for the treating.

The skilled artisan will know to adjust, within the limits discussed above, the time  
25 and temperature to achieve the desired water content. If the water content of a particular  
treated batch is lower than desired (or the acetonitrile content higher than desired), the  
batch can simply be treated further to achieve the desired levels of water and acetonitrile.

The hydrated E1, especially E1 dihydrate, obtained in this or any other  
embodiment of the present invention is substantially free of prior-art sesquihydrate. By  
30 substantially free is meant that the dihydrate contains about 5% or less of sesquihydrate.

A suitable method to determine the presence of gatifloxacin sesquihydrate in gatifloxacin form E1 is x-ray powder diffraction. Determination of presence of sesquihydrate in form E1 is feasible in the region  $7^{\circ}$  to  $9^{\circ} 2\theta$ , where a peak of sesquihydrate appears at about  $7.8^{\circ} 2\theta$ .

5           Moreover, the dihydrate of the present invention is stable against transformation to the sesquihydrate when exposed at ambient temperature to 60% relative humidity for one week. A sample is considered stable if the sesquihydrate content does not rise by an amount detectable by PXRD, described above, upon storage.

10           The E1 dihydrate of the present invention is stable against transformation to sesquihydrate when stored at  $30^{\circ}\text{C}$  and 60% relative humidity for 3 months.

15           In another embodiment, the present invention provides a novel crystalline form of gatifloxacin, denominated form F, characterized by x-ray reflections at  $8.0^{\circ}$ ,  $14.2^{\circ}$ ,  $18.7^{\circ}$ ,  $21.8^{\circ}$ , and  $23.0^{\circ} \pm 0.2^{\circ} 2\theta$ . A typical x-ray diffraction diagram of form F is shown in Figure 17. A typical DSC thermogram of form F is shown in Figure 18. A typical TGA thermogram of form F is shown in Figure 19.

20           Form F can be made by a crystallization method including the steps of providing a solution, about 25% solids, of gatifloxacin in a mixture of methanol and water, 90:10 (v:v); cooling the solution, especially to ambient temperature or below; and isolating the crystalline form of gatifloxacin from the suspension. Drying form F yields form G, described herein below.

          In still a further embodiment, the present invention provides a novel crystalline form of gatifloxacin, denominated form G, characterized by at least one of:

- a) x-ray reflections at about  $17.2^{\circ}$  and  $17.6^{\circ} \pm 0.2^{\circ} 2\theta$ , or
- b) FTIR absorption bands at about  $1614\text{ cm}^{-1}$  and about  $1267\text{ cm}^{-1}$ .

25           A typical x-ray diffraction diagram of form G is shown in Figure 20. A typical FTIR spectrum of form G is shown in Figure 21. A typical DSC thermogram of form G is shown in Figure 22. A typical TGA thermogram of form G is shown in Figure 23.

          Form G can be made by, for example, drying either of form A or form F at about  $50^{\circ}\text{C}$  and atmospheric pressure for at least about 20 hours.

30           In a further embodiment, the present invention provides a novel crystalline form of gatifloxacin, denominated form H. Form H is characterized by x-ray reflections at

about 6.6°, 13.2°, 19.6°, and 19.9° ± 0.2° 2θ. A typical x-ray diffraction diagram of form H toluene solvate is shown in Figure 24. A typical DSC thermogram of form H toluene solvate is shown in Figure 25. A typical TGA thermogram of form H toluene solvate is shown in Figure 26.

5           Form H can be made by a crystallization method including the steps of: providing a solution of gatifloxacin in toluene, preferably at reflux; cooling the solution to a temperature at which form H crystallizes, especially to ambient temperature or below, preferably 5°C or below, and isolating the crystalline form of gatifloxacin from the suspension.

10           Form H can also be prepared by a slurry method including the steps of slurrying gatifloxacin in toluene at ambient temperature for a slurry time and isolating the crystalline form of gatifloxacin from the slurry. Preferred slurry times are between about 8 and about 36 hours.

15           In a further embodiment, the present invention provides a novel crystalline form of gatifloxacin, denominated form I and characterized by x-ray reflections at 6.5°, 7.1°, 12.8°, 17.2°, 19.3°, and 21.0° ± 0.2°. A typical x-ray diffraction diagram of form I is shown in Figure 27. A typical DSC thermogram of form I is shown in Figure 28. A typical TGA thermogram of form I is shown in Figure 29.

          Form I can be made by a crystallization method including the steps of:

- 20           a) providing a solution of gatifloxacin in 1-butanol,  
          b) cooling the solution to a temperature at which form I crystallizes, especially to ambient temperature or below to obtain a suspension, and  
          c) isolating the crystalline form of gatifloxacin from the suspension.

          Form I converts to hereinbelow described form J upon drying.

25           In still another embodiment, the present invention provides a novel crystalline form of gatifloxacin, denominated form J, that exists as multiple solvates. Regardless of solvation, form J is characterized by x-ray reflections at about 6.7°, 11.3°, 13.8°, and 16.4° ± 0.2° 2θ. A typical FTIR spectrum of form J is shown in Figure 30. A typical DSC thermogram of form J is shown in Figure 31. A typical TGA thermogram of form J is  
30           shown in Figure 32.

          Form J as its iso-propanol solvate can be made by incubating gatifloxacin in vapors of iso-propanol, or by a crystallization method that includes the steps of:

- a) providing a solution of gatifloxacin in iso-propanol,
- b) cooling the solution to a temperature at which form J crystallizes, especially ambient temperature or below, and
- c) isolating the crystalline form of gatifloxacin.

5           Form J as its iso-propanol solvate can also be made by heating gatifloxacin form A at about 40° to about 70°C, preferably about 50°C, and atmospheric pressure.

          Form J as its methyl ethyl ketone solvate can be made by incubating gatifloxacin in vapors of methyl ethyl ketone.

10           Form J as its acetone solvate can be made by a slurry process including the steps of slurring gatifloxacin in acetone at ambient temperature, and isolating the crystalline acetone solvate form J gatifloxacin from the slurry.

          Form J as its tetrahydrofuran solvate can be made by a slurry process including the steps of slurring gatifloxacin in tetrahydrofuran at ambient temperature, and isolating the crystalline form J tetrahydrofuran solvate.

15           Form J as its 1-butanol solvate can be made by a crystallization method including the steps of:

- a) providing a solution of gatifloxacin in 1-butanol, preferably at reflux
- b) cooling the solution to a temperature at which form J crystallizes, especially ambient temperature or below, especially about 5°C, and
- 20           c) isolating the crystalline gatifloxacin form J 1-butanol solvate.

          Total loss-on-drying (LOD) values, step weight-losses, and water contents for form J as several of its solvates are summarized in Table I below.

*Table I: LOD, KF and Corresponding Solvate Formulas of form J Samples*

Solvent	Total Weight Loss By TGA (%)	Weight loss step ( $\approx 80-145^{\circ}\text{C}$ )	Karl Fisher (wt-%)	Corresponding Solvate Formula
IPA	8.7	4.1	4.01	GTF: IPA (4:1) (Theoretical value: 3.8%)
1-BuOH	10.4	7.6	2.79	GTF: n-BuOH (5:2) (Theoretical value: 7.3%)
IPA .	8.7	6.4	2.42	GTF: IPA (5:2) (Theoretical value: 6.0%)
IPA	8.3	4.9	4.84	GTF: IPA (3:1) (Theoretical value: 5.0%)
Acetone	8.9	4.3	3.45	GTF: Acetone (3:1) (Theoretical value: 4.9%)
IPA	11.4	7.8	3.13	GTF: IPA (2:1) (Theoretical value: 7.4%)

In still further embodiments, the present invention provides methods of making the prior-art crystalline form of gatifloxacin denominated form omega ( $\Omega$ ).

5 In one such embodiment, the present invention provides a crystallization method of making gatifloxacin form omega including the steps of:

- a) providing a filtered solution of gatifloxacin in acetonitrile, wherein the solution has a water content of about 5% or less, preferably about 4.5 wt% or less, at a temperature of about  $80^{\circ}\text{C}$  or higher, preferably
- 10 b) cooling the solution to a seeding temperature of about  $50^{\circ}$  to about  $56^{\circ}\text{C}$
- c) seeding the solution with gatifloxacin at the seeding temperature and, optionally, maintaining the seeded solution at the seeding temperature for a seeding time of about 30 minutes or more,
- d) cooling the seeded solution to a temperature at which form omega
- 15 crystallizes, preferably to ambient temperature or below, most preferably about  $5^{\circ}\text{C}$ , and
- e) isolating the gatifloxacin crystalline form omega.

As discussed in relation to for E1, the water content of the hot-filtered solution can be adjusted to the desired range by distilling off water-acetonitrile azeotrope.

In another embodiment, the present invention provides a method of making  
20 gatifloxacin form omega including the step of heating form J to about  $90^{\circ}$  to about  $170^{\circ}$

C, preferably about 120° C, at atmospheric pressure.

In a further embodiment, the present invention provides a method of making gatifloxacin form omega including the steps of heating form E1 at about 70° to 170°C for at least about 30 minutes.

5 In yet still a further embodiment, the present invention provides a method of making gatifloxacin form omega including the steps of heating gatifloxacin form G at about 120° C. In yet other embodiments, the present invention provides a method of making the prior art hemihydrate crystalline form of gatifloxacin, denominated T2RP, via the novel gatifloxacin E1. Thus in one embodiment, useful when the amounts of  
10 gatifloxacin are about 200 g or less, the present invention provides a method of making T2RP including the steps of slurrying gatifloxacin E1 with ethanol, isolating the solid from the slurry, and drying the solid *in vacuo* to obtain gatifloxacin T2RP.

In a related embodiment, useful with > 200 gram quantities of gatifloxacin or more, the present invention provides a method of making gatifloxacin form T2RP  
15 including the steps of slurrying kilogram quantities of gatifloxacin in ethanol isolating the solid from the slurry, and treating the isolated solid with moist air, as is done in making E1 dihydrate from E1-ACN.

In another embodiment, the present invention provides a method of making form T2RP including the step of heating, at atmospheric pressure, the prior-art sesquihydrate at  
20 about 80°to about 150°C, preferably 120° C.

In another embodiment, the present invention provides a method of making hemihydrate T2RP including the step of heating, at atmospheric pressure, novel gatifloxacin form G about 80°to about 130° C, preferably 120°C to effect the conversion.

In still yet another embodiment, the present invention provides novel crystalline  
25 gatifloxacin forms A, B, C, D, E1, F, G, H, I, and J having an average particle size of 100µm or less, preferably 50µm or less.

The present invention provides a plurality of particles of any of the gatifloxacin forms A, B, C, D, E1, F, G, H, I, and J having the diameter of all particles in the plurality equal to or less than about 100µm; preferably, equal to or less than about 50µm. Particles  
30 of the plurality will vary in characteristics and the characteristics of no individual or small proportion of the particles will materially affect the advantages afforded by this invention which may include more rapid dissolution and the potential for improved bioavailability.



Rather, the characteristics of the pharmaceutical composition are determined from a statistically significant sampling of the composition and measurement of bulk, or average, properties of the sample. Statistically significant measurements include those with a statistical sampling error of about 2% or less. The "average particle diameter" refers to the equivalent spherical diameter as determined by well-known methods, e.g., laser light scattering method, or sieving methods.

Gatifloxacin of the above-defined defined particle diameter may be produced by known methods of particle size reduction starting with crystals, powder aggregates and coarse powder of gatifloxacin of one or more of crystalline forms A, B, C, D, E1, F, G, H, I, and J. The principal operations of conventional size reduction are milling of a feedstock material and sorting of the milled material by size.

A fluid energy mill, or micronizer, is an especially preferred type of mill for its ability to produce particles of small size in a narrow size distribution. As those skilled in the art are aware, micronizers use the kinetic energy of collision between particles suspended in a rapidly moving fluid (typically air) stream to cleave the particles. The suspended particles are injected under pressure into a recirculating particle stream. Smaller particles are carried aloft inside the mill and swept into a vent connected to a dust collector. The feedstock may be pre-milled to about 150 to 850  $\mu\text{m}$ .

Examples of a useful micronizers include a fluid energy mill such as Microgrinding MC-300 KX, (Microgrinding Ltd., 6995 Molinazzo di Monteggio, CH), Alpine-Hosokawa Fluidized bed opposed jet mill, model AFG (Alpine-Hosokawa, Peter Dorfler Strs., D-8900, DE) and Sturtavent micronizer jet mill (Sturtavent, 348 Circuit St., Hanover, MA, USA). Alternatively, a pinmill such as Alpine UPZ 160 or similar equipment can be used.

The feed material to the micronizer can have an average PSD about 100-200 microns. The material is fed into the micronization system in a controlled feed rate by means of a screw feeder or a vibratory feeder. The air jet mill is operated with controlled air pressures. For the Microgrinding MC-300 KX, the feed rate is 40-60 kg/hr, the feed air pressure is 6-8.5 bar and the grinding air is 3-6 bar.

The material is fed into the mill system in a controlled feed rate by means of a screw feeder or a vibratory feeder. The mill is operated with controlled speed. For the Alpine UPZ 160, the feed rate is 60-75 kg/hr, the mill speed is 7000-15,000 rpm.

The novel crystalline forms of the present invention, as a plurality of particles of particle size  $\leq 100\mu\text{m}$ , especially  $\leq 50\mu\text{m}$ , are particularly useful for the preparation of pharmaceutical compositions.

Thus, in still yet a further embodiment, any of the novel crystalline forms of  
5    gatifloxacin, forms A, B, C, D, E1, F, G, H, I, or J described hereinabove, alone or in any combination, are formulated into a pharmaceutical composition, preferably an oral solid dosage form or a dosage form for parental administration. Preferably, the crystalline form of the gatifloxacin used in making the pharmaceutical composition has a maximum particle size of  $100\mu\text{m}$  or less, preferably  $50\mu\text{m}$  or less.

10       The pharmaceutical composition can be in the form of a solid oral dosage form (e.g., compressed tablets or capsules), or it can be in the form of a liquid oral dosage form (e.g., a solution or oral suspension). It was found that E1 is also stable in formulations at  $30^\circ\text{C}$  for at least 3 months.

Compressed tablets can be made by dry or wet granulation methods as is known in  
15    the art. In addition to the pharmaceutically active agent or drug, compressed tablets contain a number of pharmacologically inert ingredients, referred to as excipients. Some excipients allow or facilitate the processing of the drug into tablet dosage forms. Other excipients contribute to proper delivery of the drug by, for example, facilitating disintegration.

20       Excipients can be broadly classified according to their intended function. This classification is sometimes arbitrary and it is known that a particular excipient can function in more than one way or serve more than one purpose in a formulation.

Diluents increase the bulk of a solid pharmaceutical composition and may make a pharmaceutical dosage form containing the composition easier for the patient and  
25    caregiver to handle. Diluents for solid compositions include, for example, microcrystalline cellulose (e.g., AVICEL<sup>®</sup>, microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g.,  
30    EUDRAGIT<sup>®</sup>), potassium chloride, powdered cellulose, sodium chloride, sorbitol and talc.

Solid pharmaceutical compositions that are compacted into a dosage form like a tablet may include excipients whose functions include helping to bind the active ingredient and other excipients together after compression. Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g., carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g., KLUCEL<sup>®</sup>), hydroxypropyl methyl cellulose (e.g., METHOCEL<sup>®</sup>), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g., KOLLIDON<sup>®</sup>, PLASDONE<sup>®</sup>), pregelatinized starch, sodium alginate and starch. The dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach may be increased by the addition of a disintegrant to the composition.

Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g., AC-DI-SOL<sup>®</sup>, PRIMELLOSE<sup>®</sup>), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g., KOLLIDON<sup>®</sup>, POLYPLASDONE<sup>®</sup>), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g., EXPLOTAB<sup>®</sup>) and starch.

Glidants can be added to improve the flow properties of non-compacted solid compositions and improve the accuracy of dosing. Excipients that may function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate.

When a dosage form such as a tablet is made by compaction of a powdered composition, the composition is subjected to pressure from a punch and die. Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and die, which can cause the product to have pitting and other surface irregularities. A lubricant can be added to the composition to reduce adhesion and ease release of the product from the die. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.

Flavoring agents and flavor enhancers make the dosage form more palatable to the patient. Common flavoring agents and flavor enhancers for pharmaceutical products that may be included in the composition of the present invention include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid ethyl maltol, and tartaric acid.

Solid and liquid compositions may also be colored using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.

Of course, wet or dry granulate can also be used to fill capsules, for example  
5 gelatin capsules. The excipients chosen for granulation when a capsule is the intended dosage form may or may not be the same as those used when a compressed tablet dosage form is contemplated.

Selection of excipients and the amounts to use may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and  
10 reference works in the field.

In liquid pharmaceutical compositions of the present invention, one of GTF forms A, B, C, D, E1, F, G, H, I, and J, or mixtures thereof, and any other solid excipients are dissolved or suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin.

15 Liquid pharmaceutical compositions can contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier. Emulsifying agents that can be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol and  
20 cetyl alcohol.

Liquid pharmaceutical compositions of the present invention can also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract. Such agents include, for example, acacia, alginic acid, bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol,  
25 methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth and xanthan gum.

Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose,  
30 aspartame, fructose, mannitol and invert sugar can be added to improve the taste.

Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole and ethylenediamine tetraacetic acid can be added at levels safe for ingestion to improve storage stability.

A liquid composition according to the present invention can also contain a buffer such as gluconic acid, lactic acid, citric acid or acetic acid, sodium gluconate, sodium lactate, sodium citrate or sodium acetate.

The solid compositions of the present invention include powders, granulates, aggregates and compacted compositions. The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and ophthalmic administration. The most suitable route in any given case will depend on the nature and severity of the condition being treated. The dosages can be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.

Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches and lozenges as well as liquid syrups, suspensions and elixirs.

The active ingredient and excipients can be formulated into compositions and dosage forms according to methods known in the art.

A composition for tableting or capsule filling can be prepared by wet granulation. In wet granulation some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, which causes the powders to clump up into granules. The granulate is screened and/or milled, dried and then screened and/or milled to the desired particle size. The granulate can then be tableted or other excipients can be added prior to tableting, such as a glidant and/or a lubricant.

A tableting composition can be prepared conventionally by dry blending. For instance, the blended composition of the active ingredients and excipients can be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules can be compressed subsequently into a tablet.

As an alternative to dry granulation, a blended composition can be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules. Excipients that are particularly well-suited to direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.

A capsule filling of the present invention can comprise any of the aforementioned blends and granulates that were described with reference to tableting, only they are not subjected to a final tableting step.

Capsules, tablets and lozenges and other unit dosage forms may be administered  
5 in various dosages depending on the need.

The present invention can be further illustrated with the following non-limiting examples.

### EXAMPLES

#### Example 1 (form A)

10 3 g of gatifloxacin were slurried in 20 mL of iso-propanol (IPA). The mixture was slurried at ambient temperature for a slurry time of 24 hours with a magnetic stirrer. The mixture was filtered under vacuum, rinsed with iso-propanol (IPA) (10 mL) and analyzed by XRD analysis and showed to be form A.

#### Example 2 (form B):

15 3 g of gatifloxacin were slurried in 20 mL of 1-butanol. The mixture was stirred at ambient temperature for a slurry time of 24 hours with a magnetic stirrer. Then the mixture was filtered under vacuum, the isolated solid rinsed with 1-butanol (10 mL), and analyzed by XRD analysis.

A second portion of the solid obtained after filtration was dried under vacuum at  
20 50°C for 24 hours. This resulted in a partially amorphous form B.

#### Example 3 (form B):

3 g of gatifloxacin were slurried in 20 mL of EtOH absolute. The mixture was stirred at ambient temperature for a slurry time of 24 hours with a magnetic stirrer. Then the mixture was filtered under vacuum, the isolated solid rinsed with absolute EtOH (10  
25 mL), and analyzed by XRD. The product was partially amorphous form B.

#### Example 4 (form C)

3 g of gatifloxacin were slurried in 20 mL of 1-butanol. The mixture was stirred at ambient temperature for a slurry time of 24 hours with a magnetic stirrer. The mixture was then filtered under vacuum, the isolated solid rinsed with 1-butanol (10 mL), and  
30 dried at atmospheric pressure in an oven at 60°C for 24 hours.

Example 5 (form C)

5 g of gatifloxacin were suspended in 40 mL of 1-butanol. The mixture was heated to reflux temperature until complete dissolution of the material. The solution was then stirred at this temperature for 5 minutes, cooled to ambient temperature, and then to 5°C. The stirring was maintained at this temperature for one hour and then the mixture was filtered under vacuum. The solid obtained was put in an atmospheric oven at 60°C for 40 hours.

The sample was analyzed by PXRD and found to be form C.

Example 6 (form D):

3 g of gatifloxacin were slurried in 20 mL of methanol. The mixture was stirred at ambient temperature for a slurry time 24 hours with a magnetic stirrer. Then the mixture was filtered under vacuum, the isolated solid rinsed with methanol (10 mL) and analyzed by XRD.

Example 7 (form D):

2 g of gatifloxacin were put in a beaker. This beaker was put open in a bottle-containing methanol. Then this bottle was hermetically closed for 15 days in order to create an atmosphere saturated with methanol vapors. The sample was then analyzed by XRD analysis.

Example 8 (form F):

5 g of gatifloxacin were put in suspension in 20 mL of a aqueous solution of MeOH 90%. The mixture was heated to reflux temperature and a solution of MeOH 90% (109 mL) was added to complete the dissolution of the material. The solution was then stirred at this temperature for 5 minutes, cooled to ambient temperature, and then to 5°C. The mixture was maintained at this temperature for one hour and then was filtered under vacuum. The sample was analyzed by PXRD, with no further drying, and found to be form F.

Example 9 (form G):

5 g of gatifloxacin were put in suspension in 20 mL of a aqueous solution of MeOH 90%. The mixture was heated to reflux temperature and a solution of MeOH 90% (109 mL) was added to complete the dissolution of the material. The solution was then stirred at this temperature for 5 minutes, cooled to ambient temperature, and then to 5°C.

The mixture was maintained at this temperature for one hour and then was filtered under vacuum. The sample was dried in an atmospheric oven at 60°C for 24 hours. These samples were analyzed by XRD analysis and found to be form G.

Example 10 (form H):

- 5           3 g of gatifloxacin were slurried in 20 mL of toluene. The mixture was stirred at ambient temperature for a slurry time of 24 hours with a magnetic stirrer. Then the mixture was filtered under vacuum, the isolated solid rinsed with toluene (10 mL). The sample was analyzed by PXRD analysis with no further drying.

Example 11 (form H):

- 10           5 g of gatifloxacin were put in suspension in 50 mL of toluene equipped with a condenser and a Dean-Stark trap. The mixture was heated to reflux until complete dissolution of the material. After 10 minutes of a strong reflux the solution was cooled to ambient temperature, and then to 5°C. The mixture was maintained at this temperature for one hour and then was filtered under vacuum. The sample was analyzed by XRD  
15 analysis with no further drying.

Example 12 (form I):

- 5 g of gatifloxacin were put in suspension in 40 mL of 1-butanol. The mixture was heated to reflux temperature until complete dissolution of the material. The solution was then stirred at this temperature for 5 minutes, cooled to ambient temperature, and then to  
20 5°C. The stirring was maintained at this temperature for one hour and then the mixture was filtered under vacuum. The sample was analyzed by XRD analysis with no further drying.

Example 13 (form J):

- 3 g of gatifloxacin were slurried in 20 mL of technical IPA. The mixture was  
25 stirred at ambient temperature for a slurry time of 24 hours with a magnetic stirrer. Then the mixture was filtered under vacuum and the isolated solid rinsed with technical IPA (10 mL). The sample was divided in two portions. The first portion was dried in a vacuum oven at 50°C for 24 hours and the second portion was dried in an atmospheric oven at 60°C for 24 hours. These two dried samples were analyzed by XRD analysis and shown  
30 to be form J.



Example 14 (form J):

2 g of gatifloxacin were put in a beaker. This beaker was put open in a bottle-  
containing isopropanol. Then this bottle was hermetically closed for 15 days in order to  
create an atmosphere saturated with isopropanol vapors. The sample was then analyzed  
5 by XRD analysis.

Example 15 (form J):

2 g of gatifloxacin were put in a beaker. This beaker was put open in a bottle-  
containing methylethyl ketone. Then this bottle was hermetically closed for 15 days in  
order to create an atmosphere saturated with methylethyl ketone vapors. The sample was  
10 then analyzed by XRD analysis.

Example 16 (form J):

3 g of gatifloxacin were slurried in 20 mL of acetone. The mixture was stirred at  
ambient temperature for a slurry time of 24 hours with a magnetic stirrer. Then the  
mixture was filtered under vacuum, and the isolated solid rinsed with acetone (10 mL).  
15 The sample was divided in two portions. The first portion was not dried and the second  
portion was dried in a vacuum oven at 50°C for 24 hours. These two samples were  
analyzed by XRD analysis and found to be form J.

Example 17 (form J):

3 g of gatifloxacin were slurried in 20 mL of THF. The mixture was stirred at  
20 ambient temperature for a slurry time of 24 hours with a magnetic stirrer. Then the  
mixture was filtered under vacuum, rinsed with THF (10 mL). The sample was divided in  
two portions. The first portion was not dried and the second portion was dried in a  
vacuum oven at 50°C for 24 hours. These two samples were analyzed by XRD analysis  
and found to be form J.

25 Example 18 (form J):

5 g of gatifloxacin were put in suspension in 30 mL of technical IPA. The  
mixture was heated to reflux temperature and IPA (39mL) was added to get the complete  
dissolution of the material. The solution was then stirred at this temperature for 5 minutes,  
cooled to ambient temperature, and then to 5°C. The stirring was maintained at this  
30 temperature for one hour and then the mixture was filtered under vacuum. The solid was  
divided in three portions. The first portion was not dried, the second portion was dried in

a vacuum oven at 50°C for 24 hours and the third portion was dried in an atmospheric oven at 60°C for 24 hours. These three samples were analyzed by XRD analysis and found to be form J.

Example 19 (form J):

5           5 g of gatifloxacin were put in suspension in 40 mL of 1-butanol. The mixture was heated to reflux temperature until complete dissolution of the material. The solution was then stirred at this temperature for 5 minutes, cooled to ambient temperature, and then to 5°C. The stirring was maintained at this temperature for one hour and then the mixture was filtered under vacuum. The sample was dried in a vacuum oven at 50°C for  
10       24 hours and analyzed by XRD analysis and found to be form J.

Example 20 (form E1-ACN):

Gatifloxacin (20 g) was charged to a 150 mL reactor equipped with a mechanical stirrer and thermometer. Acetonitrile (140 mL) was added and the mixture was heated to 85°C until a clear solution formed. Hyflow ® (5%) was added to the solution and the  
15       solution was stirred at 85°C for 1 hour. A hot filtration was then performed through a jacketed Buchner funnel at 80°C and the solution was transferred in a clean reactor at 85°C. The solution was then maintained at 85°C for 5 minutes, then cooled to 60°C over 30 minutes. At this temperature (seeding temperature) the solution was seeded with gatifloxacin solid, maintained for 1 hour at 60°C (i.e., seeding time = 1 hour), and then  
20       cooled to 5°C over 5 hours. The resulting suspension was then maintained at 5°C for 1 hour. The mixture was filtered under vacuum. The isolated solid was washed with acetonitrile (15 mL) and dried in a vacuum oven at 50°C overnight.

The dry sample was analyzed by XRD and found have the characteristic XRD reflections of form E1.

25       Example 21 (hydrated E1)

A 1 liter reactor equipped with mechanical stirrer, condenser and thermometer, was charged with gatifloxacin (crude dry; 100 g) and acetonitrile (ACN 1000 mL). The slurry was then heated to reflux (80°C) and stirred at a rate of 400 rpm. The heating was continued for 0.5 hours until clear solution was obtained.

30           The clear solution was cooled to 56-58°C and seeded with 0.1 g of GTF. At the end of the addition the seeded solution was maintained for a seeding time of 2 hours at

the seeding temperature of 56-58°C, then cooled over 8 hours to a temperature of 5°C. The temperature was maintained at 5°C, with stirring for 12 hours.

The resulting slurry was filtered (suction) and the collected solid washed with ACN (150 mL) to obtain 91.7 g of wet material.

5        The wet sample was analyzed by XRD and found to be E1 (Water content by KF=2.48 wt%).

The material obtained was loaded into a Fluidized bed drier and treated at 50°C for 4 hours with to obtain 84 g of gatifloxacin crystals, form E1 dihydrate.

10        The sample was analyzed by XRD and found to be E1 (Water content by KF=8.25 wt%).

#### Example 22 (E1-ACN):

2 g of gatifloxacin were put in a beaker. This beaker was put open in a bottle-containing acetonitrile. Then this bottle was hermetically closed for 15 days in order to  
15        create an atmosphere saturated with acetonitrile vapors. The sample was then analyzed by XRD analysis.

#### Example 23 (Form Ω):

Gatifloxacin (crude, 15 g) was charged to a 250 mL reactor equipped with a mechanical stirrer and thermometer. Acetonitrile (110 mL) was added and the mixture  
20        was heated to 85°C until a clear solution formed. Hyflow® (5%) was added to the solution was stirred at 85° C for 30 minutes. A hot filtration was then performed through a jacketed Buchner funnel at 80°C and the solution was charged to a reactor at 85°C. The solution was maintained at 85°C for 1h30, then cooled to 55°C over 1 hour. At 55°C the solution was seeded with gatifloxacin solid and maintained for 30 minutes at 55°C. The  
25        resulting suspension was then cooled to 50°C over 30 minutes, maintained at this temperature for 30 minutes, cooled to 5°C over 2 hours, and maintained at 5°C for 1 hour. The mixture was filtered under vacuum and dried in a vacuum oven at 50°C overnight.

The dry sample was analyzed by XRD and found to be form Ω.

Example 24 (T2RP):

Form E1 (1 g) was slurried in 6.6 mL of ethanol and stirred at ambient temperature for 2 hours. The slurry was then filtered under vacuum and the collected solid washed with ethanol (3 ml). The washed collected solid was then dried at 50°C overnight and was analyzed by XRD analysis and shown to be form T2RP.

Example 25 (T2RP):

3g of dry form  $\Omega$  were put in a flask equipped with a condenser and a magnetic stirrer. Ethanol (19.8 mL) was added and the slurry was stirred at ambient temperature for 4 hours. A portion of the solid isolated from the slurry was dried at 50°C under vacuum until constant weight and then was analyzed by XRD. This sample was form T2RP.

Example 26 (form T2RP hemihydrate):

A 10 liter reactor equipped with mechanical stirrer, condenser and thermometer, was charged with GTF-Crude dry (1 Kg) and acetonitrile (10 liter). The slurry was then heated to reflux (80°C) and stirred at a rate of 400 rpm for 2 hours at this temperature to obtain a solution. The solution was filtered. The clear solution was cooled to 56-58°C and gatifloxacin T2RP hemihydrate (0.1 g) was added.

After seeding, the seeded solution was stirred for a seeding time of 2 hours at the seeding temperature of 56-58°C, cooled to 5°C over about 8 hours, and maintained with stirring for 2 hours at this temperature. The resulting slurry was filtered under vacuum and the collected solid washed with acetonitrile (1.5 L) to obtain 865.3 g of wet material.

The wet material was charged to a 10 L reactor and EtOH (6 L) was then charged to the reactor. The slurry was stirred at 25°C for 24 hours. The slurry was filtered under vacuum and washed with EtOH (1 L).

The wet material was loaded into a fluidized bed apparatus and treated at 50°C for 4 hours.

After treatment in the fluidized bed drier, the material was found to be form T2RP by XRD analysis.

Example 27 (hydrated E1):

A 140 liter reactor equipped with mechanical stirrer, condenser and thermometer, was charged with dimethyl sulfoxide (DMSO, 120 L). The DMSO was heated to 55°C

and the reactor was charged with 2-methylpiperazine (8.6 kg ). Gatifloxacin acid was charged, in four portions, every 2 hours ( 3 x 4 = 12 Kg). The reaction mixture was stirred at a rate of 110 rpm under nitrogen atmosphere. The temperature was maintained for 24 hours until completion of the reaction. The reaction mixture was cooled to 48°C and water (24 L) was added at this temperature. The mixture was cooled to 5°C during 3.5 hours and maintained with stirring for 15 hours at this temperature. The mixture was filtered (suction) and washed with acetonitrile (18 L) to obtain 15.9 Kg of gatifloxacin.

A 140 liter reactor equipped with mechanical stirrer, condenser and thermometer, was charged with the wet product from above (13.3 Kg, 10-20% wetness) and 72 liter of water. The mixture was stirred at 25°C for 1 hr. The slurry was filtered under vacuum and washed with acetonitrile (21 L) to obtain gatifloxacin wet material (17.5 Kg, about 50% wetness).

A 140 liter reactor equipped with mechanical stirrer, condenser and thermometer, was charged with the wet material from the previous step (8.4 kg) and with acetonitrile (70.9 L). The mixture was then heated to reflux (80°C) and stirred at a rate of 110 rpm. The heating was continued for 0.5 hours until a clear solution was obtained. The clear solution was cooled to 60°C and solvent was distilled-off under vacuum (100mm Hg). After 3 hr, essentially all the solvent was removed. Acetonitrile (49 L) was charged and the mixture was heated to reflux (80°C). The heating was continued for 0.5 hours until a clear solution was obtained.

The clear solution was filter through a- 5, 1, 0.2-micron filter. Then 500 ml of water was added and the clear solution was cooled to 62°C and gatifloxacin (0.1 gr) was added. After addition, the stirring was maintained for 2 hours at 62°C, then the mixture was cooled during 3 hours to 5°C and maintained with the stirring for 1 hours at this temperature. The resulting slurry was filtered under vacuum and washed with acetonitrile (5L) to obtain 5 kg of wet material.

The wet sample was form E1 by PXRD.

A portion of the wet material was loaded into a fluidized bed drier and dried at 25°C for 6 hours. Gatifloxacin E1 dihydrate was obtained (water content by Karl-Fisher, 9.4%).

Example 28 (E1 dihydrate):

1Kg of gatifloxacin form E1 (6.5% water content by KF) was packed into a Fluidized bed drier and treated at 25°C for 6 hours. Gatifloxacin form E1 dihydrate was obtained (9.4% water content by Karl-Fisher).

Example 29 Interconversion of forms by thermal treatment:

5 Approximately 200 mg of several of the novel crystalline forms of the present invention, prepared as described in the foregoing examples, and several of the prior-art crystalline forms were subjected to various thermal treatments. The treatments and the results are described in Table II below

*Table II: XRD results of Gatifloxacin samples before and after heating*

10

Starting form	Heating conditions	form Obtained
A	50°C, 24h, vacuum or 60C, 24h	J
B	50°C, 24h, vacuum	C
F	50°C, 24h, vacuum	G
G	120°C, 1h	Omega <sup>1</sup> .
I	60°C, 24h, Atmospheric pressure	C
J	120°C, 1h	omega
sesquihydrate	120°C, 1h	T2RP+omega
Hemihydrate	120°C, 1h	T2RP
T1RP	120°C, 1h	Hemihydrate

<sup>1</sup>Contains few additional XRD peaks

Example 30

200mg of gatifloxacin form J were put in 80% relative humidity for 1 week. The resulting sample was analyzed by XRD, TGA and KF. The resulting sample was found to  
15 have the crystal structure of the sesquihydrate (LOD= 7.8%, KF=6.6%).

Example 31

200mg of gatifloxacin omega form were put in 80% relative humidity for 1 week, and then analyzed by XRD and by TGA. The resulting sample was found to have sesquihydrate crystal structure (LOD= 7.7%).

20 Example 32

200 mg of gatifloxacin form E1 were heated to 100°C for 1 hour. The XRD of the resulting sample was that of the omega form.

We claim:

1. A crystalline form of gatifloxacin, denominated form A, characterized by x-ray reflections at about  $6.4^{\circ}$ ,  $12.8^{\circ}$ ,  $16.4^{\circ}$ ,  $17.3^{\circ}$ , and  $19.4^{\circ} \pm 0.2^{\circ} 2\theta$ .
- 5 2. The crystalline form of gatifloxacin of claim 1 having an x-ray diffraction diagram substantially as shown in Figure 1.
3. The crystalline form of gatifloxacin of claim 2 having a DSC thermogram substantially as shown in Figure 2.
- 10 4. Gatifloxacin form A characterized by x-ray reflections at  $6.4^{\circ}$ ,  $12.8^{\circ}$ ,  $16.4^{\circ}$ ,  $17.3^{\circ}$ , and  $19.4^{\circ} \pm 0.2^{\circ} 2\theta$  and a DSC thermogram substantially as shown in Figure 2.
5. A crystalline form of gatifloxacin, denominated form B, characterized by x-ray  
15 reflections at about  $9.2^{\circ}$ ,  $10.6^{\circ}$ ,  $11.9^{\circ}$ ,  $18.4^{\circ}$ , and  $25.0^{\circ} \pm 0.2^{\circ} 2\theta$ .
6. The crystalline form of gatifloxacin of claim 5 having an x-ray diffraction diagram substantially as shown in Figure 4.
- 20 7. The crystalline form of gatifloxacin of claim 6 having a DSC thermogram substantially as shown in Figure 5.
- 8 A method of making the crystalline form of gatifloxacin of claim 5 comprising the steps of:  
25 a) slurring gatifloxacin in a lower alkanol selected from ethanol and 1-butanol at ambient temperature for a slurry time, and  
b) isolating the crystalline form of gatifloxacin from the slurry.
9. The method of claim 8 wherein the slurry time is about 8 to about 36 hours.



10. Gatifloxacin crystalline form B characterized by x-ray reflections at about 9.2°, 10.6°, 11.9°, 18.4°, and  $25.0^\circ \pm 0.2^\circ 2\theta$  and a DSC thermogram substantially as shown in Figure 5.

5

11. A crystalline form of gatifloxacin, denominated form C, having at least one characteristic selected from:

- a) x-ray reflections at about 7.2°, 10.8°, 15.8°, 21.8°, and  $26.2^\circ \pm 0.2^\circ 2\theta$ ,
- b) DSC endotherms at about 173° and 177° C, and
- 10 c) FTIR absorption bands at about 805, 1509, 1619, and 1728  $\text{cm}^{-1}$ .

12. The crystalline form of gatifloxacin of claim 11 characterized by x-ray reflections at about 7.2°, 10.8°, 15.8°, 21.8°, and  $26.2^\circ \pm 0.2^\circ 2\theta$ .

15 13. The crystalline form of gatifloxacin of claim 12 having an x-ray diffraction diagram substantially as shown in Figure 7.

14. The crystalline form of gatifloxacin of claim 11 characterized by FTIR absorption bands at about 805, 1509, 1619, and 1728  $\text{cm}^{-1}$ .

20

15. The crystalline form of gatifloxacin of claim 14 having a FTIR absorption spectrum substantially as shown in Figure 8.

16. The crystalline form of gatifloxacin of claim 11 characterized by DSC endotherms  
25 at about 173° and 177°C.

17. The crystalline form of gatifloxacin of claim 16 having a DSC thermogram substantially as shown in Figure 9.

18. A method of making the crystalline form of gatifloxacin of claim 11 comprising the step of heating gatifloxacin form B at about 40° to about 70° C and atmospheric pressure for about 25 to about 48 hours.
- 5 19. The method of claim 18 wherein the heating is at about 50°C.
20. A method of making the crystalline form of gatifloxacin of claim 11 comprising the step of heating gatifloxacin form I at about 40° to about 70°C and atmospheric pressure for about 25 to about 48 hours.
- 10 21. The method of claim 20 wherein the heating is at about 60° C.
22. Gatifloxacin crystalline form C characterized by:
- 15 a) x-ray reflections at about 7.2°, 10.8°, 15.8°, 21.8°, and  $26.2^\circ \pm 0.2^\circ 2\theta$ ,  
b) DSC endotherms at about 173° and 177° C, and  
c) FTIR absorption bands at about 805, 1509, 1619, and 1728  $\text{cm}^{-1}$ .
23. A crystalline form of gatifloxacin, denominated form D, characterized by x-ray  
20 reflections at about 8.2°, 14.4°, 19.0°, 21.4°, 21.9°, and  $23.1^\circ \pm 0.2^\circ 2\theta$ .
24. The crystalline form of gatifloxacin of claim 23 having an x-ray diffraction diagram substantially as shown in Figure 11.
- 25 25. The crystalline form of gatifloxacin of claim 24 having a DSC thermogram substantially as shown in Figure 12.

26. A method of making the crystalline form of gatifloxacin of claim 23 comprising the steps of:

a) slurring gatifloxacin in methanol at ambient temperature for a slurry time, and

5 b) isolating the crystalline form of gatifloxacin from the slurry.

27. The method of claim 26 wherein the slurry time is about 8 to about 36 hours.

28. A method of making the crystalline form of gatifloxacin of claim 23 comprising  
10 the step of incubating gatifloxacin in vapors of methanol.

29. A crystalline form of gatifloxacin, denominated form F, characterized by x-ray reflections at  $8.0^\circ$ ,  $14.2^\circ$ ,  $18.7^\circ$ ,  $21.8^\circ$ , and  $23.0^\circ \pm 0.2^\circ 2\theta$ .

15 30. The crystalline form of gatifloxacin of claim 29 having an x-ray diffraction diagram substantially as shown in Figure 17.

31. The crystalline form of gatifloxacin of claim 30 having a DSC thermogram substantially as shown in Figure 18.

20

32. A method of making the crystalline form of gatifloxacin of claim 29 comprising the steps of:

a) providing a solution of gatifloxacin in a mixture of methanol and water,  
90:10 (v:v),

25

b) cooling the solution, and

c) isolating the crystalline form of gatifloxacin.

33. The method of claim 32 wherein the solution is cooled to about  $5^\circ\text{C}$ .

34. Gatifloxacin in crystalline form F characterized by x-ray reflections at  $8.0^\circ$ ,  $14.2^\circ$ ,  $18.7^\circ$ ,  $21.8^\circ$ , and  $23.0^\circ \pm 0.2^\circ 2\theta$ ; an x-ray diffraction diagram substantially as shown in Figure 17; and a DSC thermogram substantially as shown in Figure 18.
- 5 35. A crystalline form of gatifloxacin, denominated form G, characterized by at least one of:
- a) x-ray reflections at about  $17.2^\circ$  and  $17.6^\circ \pm 0.2^\circ 2\theta$ , and
  - b) FTIR absorption bands at about  $1614\text{ cm}^{-1}$  and about  $1267\text{ cm}^{-1}$ .
- 10 36. The crystalline form of gatifloxacin of claim 35 characterized by x-ray reflections at about  $17.2^\circ$  and  $17.6^\circ \pm 0.2^\circ 2\theta$ .
37. The crystalline form of gatifloxacin of claim 36 having an x-ray diffraction diagram substantially as shown in Figure 20.
- 15 38. The crystalline form of gatifloxacin of claim 35 characterized by FTIR absorption bands at about  $614$  and about  $1267\text{ cm}^{-1}$ .
39. The crystalline form of gatifloxacin of claim 38 having an FTIR absorption
- 20 spectrum substantially as shown in Figure 21.
40. The crystalline form of gatifloxacin of claim 39 having a DSC thermogram substantially as shown on Figure 22.
- 25 41. A method of making the crystalline form of gatifloxacin of claim 35 comprising the step of drying a crystalline form of gatifloxacin selected from form A and form F at  $50^\circ\text{C}$  and atmospheric pressure for at least about 20 hours.

42. A crystalline form of gatifloxacin, denominated form H, characterized by x-ray reflections at about  $6.6^\circ$ ,  $13.2^\circ$ ,  $19.6^\circ$ , and  $19.9^\circ \pm 0.2^\circ 2\theta$ .
43. The crystalline gatifloxacin of claim 42 that is a toluene solvate.
- 5
44. The crystalline form of gatifloxacin of claim 42 having an x-ray diffraction diagram substantially as shown in Figure 24.
45. The crystalline form of gatifloxacin of claim 44 having a DSC thermogram substantially as shown in Figure 25.
- 10
46. A method of making the crystalline form of gatifloxacin of claim 42 comprising the steps of:
- a) providing a solution of gatifloxacin in toluene,
  - b) cooling the solution, and
  - c) isolating the crystalline form of gatifloxacin.
- 15
47. The method of claim 46 wherein the solution is provided at reflux.
48. The method of claim 46 wherein the solution is cooled to about  $-5^\circ \text{C}$ .
- 20
49. A method of making the crystalline form of gatifloxacin of claim 42 comprising the steps of:
- a) slurrying gatifloxacin in toluene at ambient temperature for a slurry time, and
  - b) isolating the crystalline form of gatifloxacin from the slurry.
- 25
50. The method of claim 49 wherein the slurry time is about 8 to about 36 hours.

51. Gatifloxacin crystalline form H characterized by x-ray reflections at about 6.6°, 13.2°, 19.6°, and 19.9° ± 0.2°2θ; an x-ray diffraction diagram substantially as shown in Figure 24, and a DSC thermogram substantially as shown in Figure 25.

5

52. A crystalline form of gatifloxacin, denominated form I, characterized by x-ray reflections at 6.5°, 7.1°, 12.8°, 17.2°, 19.3°, and 21.0° ± 0.2°.

53. The crystalline form of gatifloxacin of claim 52 having an x-ray diffraction diagram substantially as shown in Figure 27.

10

54. The crystalline form of gatifloxacin of claim 53 having a DSC thermogram substantially as shown in Figure 28.

55. A method of making the crystalline form of gatifloxacin of claim 52 comprising the steps of:

15

- a) providing a solution of gatifloxacin in 1-butanol,
- b) cooling the solution, and
- c) isolating the crystalline form of gatifloxacin.

20

56. The method of claim 55 wherein the solution is provided at reflux.

57. The method of claim 55 wherein the cooling is to about -5° C.

58. Crystalline gatifloxacin form I characterized by x-ray reflections at 6.5°, 7.1°, 12.8°, 17.2°, 19.3°, and 21.0° ± 0.2°; an x-ray diffraction diagram substantially as shown in Figure 27; and a DSC thermogram substantially as shown in Figure 28.

25

59. A crystalline form of gatifloxacin that is a solvate, denominated form J, characterized by x-ray reflections at about 6.7°, 11.3°, 13.8°, and 16.4°± 0.2° 2θ.

60. The crystalline form of gatifloxacin of claim 59 that is an iso-propanol solvate.

5

61. A method of making the crystalline form of claim 60 comprising the step of incubating gatifloxacin in vapors of iso-propanol.

62. A method of making the crystalline form of gatifloxacin of claim 60 comprising the steps of:

- 10
- a) providing a solution of gatifloxacin in iso-propanol,
  - b) cooling the solution, and
  - c) isolating the crystalline form of gatifloxacin.

15 63. A method of making the crystalline form of gatifloxacin of claim 60 comprising the step of heating gatifloxacin form A at about 40°C to about 70° C and atmospheric pressure.

64. The method of claim 63 wherein the heating is at about 50°C.

20

65. The crystalline form of gatifloxacin of claim 59 that is a methyl ethyl ketone solvate.

66. A method of making the crystalline form of claim 65 comprising the step of incubating gatifloxacin in vapors of methyl ethyl ketone.

25

67. The crystalline form of claim 59 that is an acetone solvate.

68. A method of making the crystalline form of gatifloxacin of claim 67 comprising the steps of:

- a) slurrying gatifloxacin in acetone at ambient temperature, and
- b) isolating the crystalline form of gatifloxacin from the slurry.

5

69. The crystalline form of claim 59 that is a tetrahydrofuran solvate.

70. A method of making the crystalline form of claim 69 comprising the steps of:

- a) slurrying gatifloxacin in tetrahydrofuran at ambient temperature, and
- b) isolating the crystalline form of gatifloxacin from the slurry.

10

71. The crystalline form of claim 59 that is a 1-butanol solvate.

72. A method of making the crystalline form of gatifloxacin of claim 71 including the steps of:

15

- a) providing a solution of gatifloxacin in 1-butanol,
- b) cooling the solution, and
- c) isolating the crystalline form of gatifloxacin.

20 73. The method of claim 72 wherein the solution is provided at reflux.

74. The method of claim 72 wherein the solution is cooled to about -5°C.

75. Gatifloxacin butanol solvate.

25

76. A crystalline form of gatifloxacin characterized by x-ray reflections at about 7.1°, 7.3°, 10.8°, 15.7°, 16.4°, and 18.1° ± 0.2° 2θ.



77. The crystalline form of claim 76 containing acetonitrile, water, or mixtures thereof up to about 10% by weight.
78. A method of making the crystalline form of gatifloxacin of claim 77 comprising  
5 the step of treating E1-ACN in a fluidized bed apparatus.
79. The method of claim 78 wherein the E1-ACN treated with moist gas at a temperature greater than about 30° C.
- 10 80. The crystalline form of gatifloxacin of claim 77, designated E1-ACN, comprising up to about 10% by weight acetonitrile.
81. The crystalline form of gatifloxacin of claim 77, designated E1 hydrate, comprising about 7.5% to 10% by weight water.
- 15 82. A method of making the crystalline form of gatifloxacin of claim 81 comprising the step of treating E1-ACN with moist gas in a fluidized bed apparatus at a temperature greater than about 30° C.
- 20 83. The method of making the crystalline form of gatifloxacin of claim 82 wherein the gatifloxacin treated is first treated with moist gas at 20° to 30° C.
84. A method of making the crystalline form of gatifloxacin of claim 81 comprising the step of exposing E1-ACN to 60% relative humidity.
- 25 85. The crystalline form of claim 81, comprising about 9.3% water, denominated gatifloxacin form E1 dihydrate.

86. Gatifloxacin E1- dihydrate.

87. The crystalline form of gatifloxacin of claim 76 having an x-ray diffraction diagram substantially as shown in Figures 14a through 14g.

5

88. A method of making the crystalline form of gatifloxacin a claim 80 comprising the steps of:

a) providing a solution of gatifloxacin in acetonitrile having about 5 wt% or less water at reflux,

10 b) cooling the solution to a seeding temperature of about 57° to 70°C,

c) seeding the solution at the seeding temperature,

d) cooling the seeded solution, and

e) isolating the crystalline form of gatifloxacin.

15 89. The method of claim 88 wherein the seeded solution is maintained at the seeding temperature for a seeding time of at least about 30 minutes.

90. The method of claim 88 wherein the seeding temperature is about 60°C.

20 91. The method of claim 88 wherein the seeded solution is cooled to about 5°C or below.

92. The method of claim 88 wherein the solution of gatifloxacin in acetonitrile has about 4.5 wt% or less water.

25

93. A method of making the crystalline form of gatifloxacin of claim 80 comprising the step of incubating gatifloxacin in acetonitrile vapors.

94. A crystalline form of gatifloxacin, denominated E1-ACN, having up to about 10% acetonitrile and characterized by x-ray reflections at about 7.1°, 7.3°, 10.8°, 15.7°, 16.4°, and  $18.1^\circ \pm 0.2^\circ 2\theta$ , wherein the crystalline form is made by a process comprising the steps of:

- 5                   a) providing a solution of gatifloxacin in acetonitrile having about 5 wt% or less water at reflux,
- b) cooling the solution to a seeding temperature of about 57° to 70°C,
- c) seeding the solution at the seeding temperature,
- d) cooling the seeded solution, and
- 10                  e) isolating the crystalline form of gatifloxacin.

95. The crystalline form of gatifloxacin of claim 94 wherein the solution of gatifloxacin in acetonitrile has about 4.5 wt% or less water.

- 15   96. The crystalline form of claim 94 wherein the seeded solution is maintained at the seeding temperature for a seeding time of at least about 30 minutes.

97. The crystalline form of claim 94 wherein the seeding temperature is about 60° C.

- 20   98. The crystalline form of claim 94 wherein the seeded solution is cooled to about 5°C or below.

99. A method of making gatifloxacin crystalline form omega comprising the steps of:

- a) providing a filtered solution of gatifloxacin in acetonitrile, wherein the
- 25   solution has a water content of about 5 wt% or less, at reflux,
- b) cooling the solution to a seeding temperature of about 50° to about 56° C
- c) seeding the solution with gatifloxacin at the seeding temperature,
- d) cooling the seeded solution, and
- e) isolating the crystalline gatifloxacin crystalline form omega.

100. The method of claim 99 wherein the solution of gatifloxacin in acetonitrile has a water content of about 4.5 wt% or less.

5 101. The method of claim 99 wherein the solution is held at the seeding temperature for a seeding time of at least about 30 minutes.

102. The method of claim 99 wherein the seeded solution is cooled to a temperature of 5° C or below.

10

103. A method of making crystalline gatifloxacin form omega comprising the step of heating form J at about 90° to about 170° C and atmospheric pressure.

104. The method of claim 103 wherein the heating is at about 120°C.

15

105. A method of making gatifloxacin form omega comprising the step of heating form E1 at about 70° - 170° C.

106. The method of claim 105 wherein the treating is at about 100° C.

20

107. A method of making gatifloxacin form omega comprising the step of heating gatifloxacin form G at about 100° - 150° C.

25 108. A method of making a hydrated gatifloxacin form E1 comprising the step of treating gatifloxacin form E1-ACN solvate with a moist gas at a temperature from ambient temperature to about 60° C.

109. The method of claim 108 wherein the treating is at about 20° to about 30°C and the E1 dihydrate has a water content of about 7.5% to about 10% on a weight basis.

110. The method of claim 108 wherein the moist gas has a relative humidity between  
5 about 55% and about 75%.

111. The method of claim 108 wherein the treating is at about 50°C.

112. The method of claim 108 wherein the treating is effected in a fluidized bed drying  
10 apparatus.

113. A hydrated crystalline form of gatifloxacin having up to about 10% water or a mixture of water and acetonitrile and characterized by x-ray reflections at about 7.1°, 7.3°, 10.8°, 15.7°, 16.4°, and  $18.1^\circ \pm 0.2^\circ 2\theta$ , wherein the crystalline form is made by a  
15 process comprising the step of treating gatifloxacin E1-ACN with moist gas at a temperature from ambient to about 60° C.

114. The crystalline form of gatifloxacin of claim 113 wherein the treating is at about 20° to about 30°C and the crystalline form contains about 5% to about 7% water.  
20

115. The crystalline form of claim 113 wherein the relative humidity of the moist gas is about 55% to about 75%.

116. The crystalline form of gatifloxacin of claim 113 wherein the treating is at about  
25 50° C.

117. The crystalline form of claim 113 wherein the treating is in a fluidized bed apparatus.

118. A method of making of gatifloxacin form T2RP comprising the steps of heating a hemihydrate of gatifloxacin at about 80°C to about 150°C.
- 5 119. The method of claim 118 wherein the heating is to a temperature of about 120°C.
120. A method of making a hemihydrate of gatifloxacin comprising the step of heating form G at a temperature of about 80° to about 130°C.
- 10 121. The method of claim 120 wherein the temperature is about 120°C.
122. A method of making a mixture of forms omega and T2RP comprising the step of heating gatifloxacin sesquihydrate at 120°C.
- 15 123. Gatifloxacin form E1 dihydrate that contains 5% or less of the sesquihydrate.
124. Gatifloxacin form E1 dihydrate that remains substantially free of gatifloxacin sesquihydrate upon storage at ambient temperature and 60% relative humidity for 3 months.
- 20 125. Gatifloxacin having a particle size up to about 100µm wherein the gatifloxacin is in a crystalline form selected from forms A, B, C, D, hydrated E1, F, G, H, I, and J.
126. The gatifloxacin according to claim 125 wherein the particle size is about 50µm or less.
- 25 127. A pharmaceutical composition comprising at least one crystalline form of gatifloxacin selected from forms A, B, C, D, hydrated E1, F, G, H, I, and J; and at least one pharmaceutically acceptable excipient.

128. A pharmaceutical composition comprising hydrated gatifloxacin crystalline form E1 substantially free of gatifloxacin sesquihydrate.
- 5 129. A pharmaceutical composition comprising gatifloxacin form E1 hydrate that is stable against transformation to sesquihydrate when stored at 30° C and 60% relative humidity for 3 months.
- 10 130. A method of making about 200 g or less of gatifloxacin form T2RP comprising the steps of:
- slurrying about 200 g or less of gatifloxacin E1-ACN in ethanol at ambient temperature,
  - isolating the solid from the slurry,
  - drying the isolated solid at 50° C.
- 15 131. A method of making about 200 g or more of gatifloxacin form T2RP comprising the steps of:
- slurrying at least about 200 g gatifloxacin E1-ACN in ethanol at ambient temperature,
  - isolating the solid from the slurry,
  - 20 treating the isolated solid in a fluidized bed apparatus.

1/38




Fig. 1



2/38




Fig. 2

3/38




Fig. 3

4/38




Fig. 4

5/38




Fig. 5

6/38




Fig. 6

7/38




Fig. 7

8/38




Fig. 8

9/38




Fig. 9



10/38




Fig. 10

11/38




Fig. 11

12/38




Fig. 12

13/38




Fig. 13

14/38




Fig. 14a

15/38




Fig. 14b

16/38




Fig. 14c

17/38




Fig. 14d

SUBSTITUTE SHEET (RULE 26)



18/38




Fig. 14e

19/38




Fig. 14f

SUBSTITUTE SHEET (RULE 26)

20/38




Fig. 14g

21/38




Fig. 15

22/38




Fig. 16

23/38




Fig. 17

24/38




Fig. 18

25/38




Fig. 19



26/38




Fig. 20

27/38




Fig. 21

28/38




Fig. 22

SUBSTITUTE SHEET (RULE 26)

29/38




Fig. 23

30/38




Fig. 24

31/38




Fig. 25

32/38




Fig. 26

33/38




Fig. 27



34/38




Fig. 28

35/38




Fig. 29




Fig. 30

37/38




Fig. 31

38/38




Fig. 32

2

1

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
20 November 2003 (20.11.2003)


PCT

(10) International Publication Number  
**WO 2003/094919 A3**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/496**,  
C07D 401/04
- (21) International Application Number:  
PCT/US2003/014811
- (22) International Filing Date: 12 May 2003 (12.05.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- |            |                                |    |
|------------|--------------------------------|----|
| 60/379,510 | 10 May 2002 (10.05.2002)       | US |
| 60/389,093 | 14 June 2002 (14.06.2002)      | US |
| 60/401,672 | 6 August 2002 (06.08.2002)     | US |
| 60/402,749 | 12 August 2002 (12.08.2002)    | US |
| 60/409,860 | 10 September 2002 (10.09.2002) | US |
| 60/423,338 | 1 November 2002 (01.11.2002)   | US |
| 60/432,961 | 12 December 2002 (12.12.2002)  | US |
| 60/444,812 | 3 February 2003 (03.02.2003)   | US |
| 60/448,062 | 15 February 2003 (15.02.2003)  | US |
- (71) Applicant (for all designated States except BB, US): **TEVA PHARMACEUTICAL INDUSTRIES LTD.** [IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petah Tiqva (IL).
- (71) Applicant (for BB only): **TEVA PHARMACEUTICALS USA, INC.** [US/US]; 1090 Horsham Road, P.O. Box 1090, North Wales, PA 19454-1090 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **NIDDAM-HILDESHEIM, Valerie** [IL/IL]; 9 Keren Hayessod, PO 1343, 40500 Even-Yeouda (IL). **WIZEL, Shlomit** [IL/IL]; Yehuda Hanassi 2, 49742 Petah Tiqva (IL). **STER-IMBAUM, Greta** [IL/IL]; 10/10 Kaplinsky St., Rishon, 75241 Lezion (IL). **AMIR, Ehud** [IL/IL]; 73 Einstein Street, Apartment 20, Ramat Aviv, 69102 Tel Aviv (IL).
- (74) Agent: **BRAINARD, Charles, R.**; Kenyon & Kenyon, One Broadway, New York, NY 10004-1050 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: NOVEL CRYSTALLINE FORMS OF GATIFLOXACIN



(57) Abstract: Provided are novel crystalline forms of gatifloxacin denominated forms A, B, C, D, E1, F, G, H, I, and J, and methods for their preparation. Also provided are methods for making known crystalline forms of hatifloxacin, in particular forms omega and T2RP.



(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) **Date of publication of the international search report:**  
18 March 2004

**Published:**

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/14811

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/496 C07D401/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02 22126 A (SQUIBB BRISTOL MYERS CO) 21 March 2002 (2002-03-21) claim 1; figure 1	1-131
X	EP 0 805 156 A (KYORIN SEIYAKU KK) 5 November 1997 (1997-11-05) cited in the application  claim 1	1-98, 103-117, 120,121, 123-131
X	EP 0 629 621 A (CHUGAI PHARMACEUTICAL CO LTD) 21 December 1994 (1994-12-21)  claim 1	1-98, 103-117, 120,121, 123-131



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

26 November 2003

Date of mailing of the international search report

09.01.04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Bérillon, L

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 03/14811

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-98, 103-117, 120-121, 123-131

Crystalline forms of gatifloxacin, preparation thereof and use thereof

2. Claims: 99-102

Process for the preparation of form omega of gatifloxacin

3. Claims: 118-119

Process for the preparation of form T2RP of gatifloxacin

4. Claim : 122

Process for the preparation of a mixture of form omega and T2RP of gatifloxacin

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/14811

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0222126	A	21-03-2002	AU 8659201 A	26-03-2002
			CA 2422616 A1	21-03-2002
			EP 1326612 A1	16-07-2003
			HU 0300972 A2	29-09-2003
			WO 0222126 A1	21-03-2002
			US 2002052379 A1	02-05-2002
EP 0805156	A	05-11-1997	JP 3449658 B2	22-09-2003
			JP 8176143 A	09-07-1996
			AT 216381 T	15-05-2002
			AU 694946 B2	06-08-1998
			AU 3994695 A	10-07-1996
			DE 69526453 D1	23-05-2002
			DE 69526453 T2	12-12-2002
			DK 805156 T3	06-05-2002
			EP 0805156 A1	05-11-1997
			US 5880283 A	09-03-1999
			CA 2208704 A1	27-06-1996
			CN 1171108 A	21-01-1998
			ES 2173982 T3	01-11-2002
			HU 77945 A2	28-12-1998
			WO 9619472 A1	27-06-1996
			PT 805156 T	30-09-2002
			TW 393479 B	11-06-2000
EP 0629621	A	21-12-1994	AT 207479 T	15-11-2001
			CA 2128601 A1	05-08-1993
			DE 69331003 D1	29-11-2001
			DE 69331003 T2	20-06-2002
			EP 0629621 A1	21-12-1994
			KR 228572 B1	01-11-1999
			US 5597923 A	28-01-1997
			ES 2167329 T3	16-05-2002
			JP 3256311 B2	12-02-2002
			JP 5271221 A	19-10-1993
			WO 9315070 A1	05-08-1993